Monitoring your symptoms and finding your own triggers can aid in customizing effective nausea management and enhancing comfort
Current research investigating potential advantages beyond glycaemic regulation and weight reduction, including impacts on non-alcoholic fatty liver disease, cardiovascular outcomes, and renal protection, may broaden the therapeutic uses of these medicines
Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): Exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials
The All of Us research program systematically maps the international code of diseases to standardized SNOMED concepts
First, 68% of all injectable device registration requests for obesity and diabetes treatment filed with Anvisa are for synthetic drugs a category that has grown rapidly since the development of laboratory-synthesized versions of the GLP-1 hormone in 2022